Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Baudax Bio, Inc. (BXRXQ : OTC)

• Company Description    Baudax Bio Inc. is a pharmaceutical company. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. Baudax Bio Inc. is based in Malvern, Pennsylvania. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: 10,102 shares Shares Outstanding: 52.46 (millions) Market Capitalization: $0.01 (millions) Beta: 0.80 52 Week High: $0.01 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week 0.00% -14.07% Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 490 LAPP ROAD - MALVERN,PA 19355 USA ph: 484-395-2440 fax: 484-395-2471 mmoyer@lifesciadvisors.com http://www.baudaxbio.com

• General Corporate Information    Officers Gerri A. Henwood - Chief Executive Officer and President Wayne B. Weisman - Chairman Jillian Dilmore - Principal Financial Officer William L. Ashton - Director Winston J. Churchill - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 07160F404 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 52.46 Most Recent Split Date: 12.00 (0.03:1) Beta: 0.80 Market Capitalization: $0.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©